[1]
|
Talmadge, J.E. and Gabrilovich, D.I. (2013) History of Myeloid-Derived Suppressor Cells. Nature Reviews Cancer, 13, 739-752. https://doi.org/10.1038/nrc3581
|
[2]
|
Keresztes, M. and Boonstra, J. (1999) Import(ance) of Growth Factors in(to) the Nucleus. The Journal of Cell Biology, 145, 421-424. https://doi.org/10.1083/jcb.145.3.421
|
[3]
|
Zhang, H., Maric, I., DiPrima, M.J., Khan, J., Orentas, R.J., Kaplan, R.N. and Mackall, C.L. (2013) Fibrocytes Represent a Novel MDSC Subset Circulating in Patients with Metastatic Cancer. Blood, 122, 1105-1113.
https://doi.org/10.1182/blood-2012-08-449413
|
[4]
|
Zoso, A., Mazza, E.M., Bicciato, S., Mandruzzato, S., Bronte, V., Serafini, P. and Inverardi, L. (2014) Human Fibrocytic Myeloid-Derived Suppressor Cells Express IDO and Promote Tolerance via Treg-Cell Expansion. European Journal of Immunology, 44, 3307-3319. https://doi.org/10.1002/eji.201444522
|
[5]
|
Ushach, I. and Zlotnik, A. (2016) Biological Role of Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) and Macrophage Colony-Stimulating Factor (M-CSF) on Cells of the Myeloid Lineage. Journal of leukocyte biology, 100, 481-489. https://doi.org/10.1189/jlb.3RU0316-144R
|
[6]
|
Hamerman, J.A., Pottle, J., Ni, M., He, Y., Zhang, Z.Y. and Buckner, J.H. (2016) Negative Regulation of TLR Signaling in Myeloid Cells—Implications for Autoimmune Diseases. Immunological Reviews, 269, 212-227.
https://doi.org/10.1111/imr.12381
|
[7]
|
Zindel, J. and Kubes, P. (2020) DAMPs, PAMPs, and LAMPs in Immunity and Sterile Inflammation. Annual Review of Pathology, 15, 493-518. https://doi.org/10.1146/annurev-pathmechdis-012419-032847
|
[8]
|
Gabrilovich, D.I., Ostrand-Rosenberg, S. and Bronte, V. (2012) Coordinated Regulation of Myeloid Cells by Tumours. Nature Reviews Immunology, 12, 253-268. https://doi.org/10.1038/nri3175
|
[9]
|
Kumar, V., Patel, S., Tcyganov, E. and Gabrilovich, D.I. (2016) The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends in Immunology, 37, 208-220. https://doi.org/10.1016/j.it.2016.01.004
|
[10]
|
Veglia, F., Perego, M. and Gabrilovich, D. (2018) Myeloid-Derived Suppressor Cells Coming of Age. Nature Immunology, 19, 108-119. https://doi.org/10.1038/s41590-017-0022-x
|
[11]
|
Park, M.Y., Lim, B.G., Kim, S.Y., Sohn, H.J., Kim, S. and Kim, T.G. (2019) GM-CSF Promotes the Expansion and Differentiation of Cord Blood Myeloid-Derived Suppressor Cells, Which Attenuate Xenogeneic Graft-vs.-Host Disease. Frontiers in Immunology, 10, Article No. 183. https://doi.org/10.3389/fimmu.2019.00183
|
[12]
|
Huang, B., Lei, Z., Zhao, J., Gong, W., Liu, J., Chen, Z., Liu, Y., Li, D., Yuan, Y., Zhang, G.M. and Feng, Z.H. (2007) CCL2/CCR2 Pathway Mediates Recruitment of Myeloid Suppressor Cells to Cancers. Cancer Letters, 252, 86-92.
https://doi.org/10.1016/j.canlet.2006.12.012
|
[13]
|
Shojaei, F., Wu, X., Zhong, C., Yu, L., Liang, X.H., Yao, J., Blanchard, D., Bais, C., Peale, F.V., van Bruggen, N., Ho, C., Ross, J., Tan, M., Carano, R.A., Meng, Y.G. and Ferrara, N. (2007) Bv8 Regulates Myeloid-Cell-Dependent Tumour Angiogenesis. Nature, 450, 825-831. https://doi.org/10.1038/nature06348
|
[14]
|
Fridlender, Z.G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G.S. and Albelda, S.M. (2009) Polarization of Tumor-Associated Neutrophil Phenotype by TGF-Beta: “N1” versus “N2” TAN. Cancer Cell, 16, 183-194.
https://doi.org/10.1016/j.ccr.2009.06.017
|
[15]
|
Xu, W., Dong, J., Zheng, Y., Zhou, J., Yuan, Y., Ta, H.M., Miller, H.E., Olson, M., Rajasekaran, K., Ernstoff, M.S., Wang, D., Malarkannan, S. and Wang, L. (2019) Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression. Cancer Immunology Research, 7, 1497-1510. https://doi.org/10.1158/2326-6066.CIR-18-0489
|
[16]
|
Mohrherr, J., Haber, M., Breitenecker, K., Aigner, P., Moritsch, S., Voronin, V., Eferl, R., Moriggl, R., Stoiber, D., Győrffy, B., Brcic, L., László, V., Döme, B., Moldvay, J., Dezső, K., Bilban, M., Popper, H., Moll, H.P. and Casanova, E. (2019) JAK-STAT Inhibition Impairs K-RAS-Driven Lung Adenocarcinoma Progression. International Journal of Cancer, 145, 3376-3388. https://doi.org/10.1002/ijc.32624
|
[17]
|
Yu, Q., Dong, L., Li, Y. and Liu, G. (2018) SIRT1 and HIF1α Signaling in Metabolism and Immune Responses. Cancer Letters, 418, 20-26. https://doi.org/10.1016/j.canlet.2017.12.035
|
[18]
|
Trikha, P. and Carson 3rd, W.E. (2014) Signaling Pathways Involved in MDSC Regulation. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1846, 55-65. https://doi.org/10.1016/j.bbcan.2014.04.003
|
[19]
|
Derynck, R. and Zhang, Y.E. (2003) Smad-Dependent and Smad-Independent Pathways in TGF-Beta Family Signalling. Nature, 425, 577-584. https://doi.org/10.1038/nature02006
|
[20]
|
Jing, B., Wang, T., Sun, B., Xu, J., Xu, D., Liao, Y., Song, H., Guo, W., Li, K., Hu, M., Zhang, S., Ling, J., Kuang, Y., Zhang, T., Zhou, B.P., Yao, F. and Deng, J. (2020) IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung. Cancer Research, 80, 784-797.
https://doi.org/10.1158/0008-5472.CAN-19-2013
|
[21]
|
Heinrich, P.C., Behrmann, I., Müller-Newen, G., Schaper, F. and Graeve, L. (1998) Interleukin-6-Type Cytokine Signalling through the gp130/Jak/STAT Pathway. The Biochemical Journal, 334, 297-314.
https://doi.org/10.1042/bj3340297
|
[22]
|
Shabani, F., Farasat, A., Mahdavi, M. and Gheibi, N. (2018) Calprotectin (S100A8/S100A9): A Key Protein between Inflammation and Cancer. Inflammation Research, 67, 801-812. https://doi.org/10.1007/s00011-018-1173-4
|
[23]
|
Luo, H.M., Wu, X., Xian, X., Wang, L.Y., Zhu, L.Y., Sun, H.Y., Yang, L. and Liu, W.X. (2020) Calcitonin Gene-Related Peptide Inhibits Angiotensin II-Induced NADPH Oxidase-Dependent ROS via the Src/STAT3 Signalling Pathway. Journal of Cellular and Molecular Medicine, 24, 6426-6437. https://doi.org/10.1111/jcmm.15288
|
[24]
|
Roy, K., Wu, Y., Meitzler, J.L., Juhasz, A., Liu, H., Jiang, G., Lu, J., Antony, S. and Doroshow, J.H. (2015) NADPH Oxidases and Cancer. Clinical Science, 128, 863-875. https://doi.org/10.1042/CS20140542
|
[25]
|
Colotta, F., Allavena, P., Sica, A., Garlanda, C. and Mantovani, A. (2009) Cancer-Related Inflammation, the Seventh Hallmark of Cancer: Links to Genetic Instability. Carcinogenesis, 30, 1073-1081.
https://doi.org/10.1093/carcin/bgp127
|
[26]
|
Zhang, Y. and Liu, Z. (2017) STAT1 in Cancer: Friend or Foe? Discovery Medicine, 24, 19-29.
|
[27]
|
Jayakumar, A. and Bothwell, A. (2017) Stat6 Promotes Intestinal Tumorigenesis in a Mouse Model of Adenomatous Polyposis by Expansion of MDSCs and Inhibition of Cytotoxic CD8 Response. Neoplasia, 19, 595-605.
https://doi.org/10.1016/j.neo.2017.04.006
|
[28]
|
Zhu, D., Tian, J., Wu, X., Li, M., Tang, X., Rui, K., Guo, H., Ma, J., Xu, H. and Wang, S. (2019) G-MDSC-Derived Exosomes Attenuate Collagen-Induced Arthritis by Impairing Th1 and Th17 Cell Responses. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1865, Article ID: 165540. https://doi.org/10.1016/j.bbadis.2019.165540
|
[29]
|
Zhang, H.G. and Grizzle, W.E. (2011) Exosomes and Cancer: A Newly Described Pathway of Immune Suppression. Clinical Cancer Research, 17, 959-964. https://doi.org/10.1158/1078-0432.CCR-10-1489
|
[30]
|
Dejima, H., Iinuma, H., Kanaoka, R., Matsutani, N. and Kawamura, M. (2017) Exosomal MicroRNA in Plasma as a Non-Invasive Biomarker for the Recurrence of Non-Small Cell Lung Cancer. Oncology Letters, 13, 1256-1263.
https://doi.org/10.3892/ol.2017.5569
|
[31]
|
Hu, H., Xu, Z., Li, C., Xu, C., Lei, Z., Zhang, H.T. and Zhao, J. (2016) MiR-145 and miR-203 Represses TGF-β-Induced Epithelial-Mesenchymal Transition and Invasion by Inhibiting SMAD3 in Non-Small Cell Lung Cancer Cells. Lung Cancer, 97, 87-94. https://doi.org/10.1016/j.lungcan.2016.04.017
|
[32]
|
Hokusai-VTE Investigators, Büller, H.R., Décousus, H., Grosso, M.A., Mercuri, M., Middeldorp, S., Prins, M.H., Raskob, G.E., Schellong, S.M., Schwocho, L., Segers, A., Shi, M., Verhamme, P. and Wells, P. (2013) Edoxaban Versus Warfarin for the Treatment of Symptomatic venous Thromboembolism. The New England Journal of Medicine, 369, 1406-1415. https://doi.org/10.1056/NEJMoa1306638
|
[33]
|
Yang, J., Yan, J. and Liu, B. (2018) Targeting VEGF/VEGFR to Modulate Antitumor Immunity. Frontiers in Immunology, 9, Article No. 978. https://doi.org/10.3389/fimmu.2018.00978
|
[34]
|
Singh, M., Ramos, I., Asafu-Adjei, D., Quispe-Tintaya, W., Chandra, D., Jahangir, A., Zang, X., Aggarwal, B.B. and Gravekamp, C. (2013) Curcumin Improves the Therapeutic Efficacy of Listeria(at)-Mage-b Vaccine in Correlation with Improved T-Cell Responses in Blood of a Triple-Negative Breast Cancer Model 4T1. Cancer Medicine, 2, 571-582. https://doi.org/10.1002/cam4.94
|
[35]
|
Faivre, S., Demetri, G., Sargent, W. and Raymond, E. (2007) Molecular Basis for Sunitinib Efficacy and Future Clinical Development. Nature Reviews Drug Discovery, 6, 734-745. https://doi.org/10.1038/nrd2380
|
[36]
|
Kujawski, M., Zhang, C., Herrmann, A., Reckamp, K., Scuto, A., Jensen, M., Deng, J., Forman, S., Figlin, R. and Yu, H. (2010) Targeting STAT3 in Adoptively Transferred T Cells Promotes Their in Vivo Expansion and Antitumor Effects. Cancer Research, 70, 9599-9610. https://doi.org/10.1158/0008-5472.CAN-10-1293
|
[37]
|
Hellsten, R., Johansson, M., Dahlman, A., Dizeyi, N., Sterner, O. and Bjartell, A. (2008) Galiellalactone Is a Novel Therapeutic Candidate against Hormone-Refractory Prostate Cancer Expressing Activated Stat3. The Prostate, 68, 269-280. https://doi.org/10.1002/pros.20699
|
[38]
|
Don-Doncow, N., Escobar, Z., Johansson, M., Kjellström, S., Garcia, V., Munoz, E., Sterner, O., Bjartell, A. and Hellsten, R. (2014) Galiellalactone Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells. The Journal of Biological Chemistry, 289, 15969-15978. https://doi.org/10.1074/jbc.M114.564252
|
[39]
|
Meyer, C., Cagnon, L., Costa-Nunes, C.M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E. and Speiser, D.E. (2014) Frequencies of Circulating MDSC Correlate with Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Cancer Immunology, Immunotherapy, 63, 247-257.
https://doi.org/10.1007/s00262-013-1508-5
|
[40]
|
Cao, Y., Slaney, C.Y., Bidwell, B.N., Parker, B.S., Johnstone, C.N., Rautela, J., Eckhardt, B.L. and Anderson, R.L. (2014) BMP4 Inhibits Breast Cancer Metastasis by Blocking Myeloid-Derived Suppressor Cell Activity. Cancer Research, 74, 5091-5102. https://doi.org/10.1158/0008-5472.CAN-13-3171
|
[41]
|
Makhmalzadeh, B.S., Molavi, O., Vakili, M.R., Zhang, H.F., Solimani, A., Abyaneh, H.S., Loebenberg, R., Lai, R. and Lavasanifar, A. (2018) Functionalized Caprolactone-Polyethylene Glycol Based Thermo-Responsive Hydrogels of Silibinin for the Treatment of Malignant Melanoma. Journal of Pharmacy & Pharmaceutical Sciences, 21, 143-159.
https://doi.org/10.18433/jpps29726
|
[42]
|
Forghani, P., Khorramizadeh, M.R. and Waller, E.K. (2014) Silibinin Inhibits Accumulation of Myeloid-Derived Suppressor Cells and Tumor Growth of Murine Breast Cancer. Cancer Medicine, 3, 215-224.
https://doi.org/10.1002/cam4.186
|
[43]
|
Highfill, S.L. Cui, Y., Giles, A.J., Smith, J.P., Zhang, H., Morse, E., et al. (2014) Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy. Science Translational Medicine, 6, Article No. 237ra67.
https://doi.org/10.1126/scitranslmed.3007974
|
[44]
|
Alkhateeb, T., Kumbhare, A., Bah, I., Youssef, D., Yao, Z.Q., McCall, C.E. and El Gazzar, M. (2019) S100A9 Maintains Myeloid-Derived Suppressor Cells in Chronic Sepsis by Inducing MiR-21 and MiR-181b. Molecular Immunology, 112, 72-81. https://doi.org/10.1016/j.molimm.2019.04.019
|
[45]
|
Cheng, P., Eksioglu, E.A., Chen, X., Kandell, W., Le Trinh, T., Cen, L., Qi, J., Sallman, D.A., Zhang, Y., Tu, N., Adams, W.A., Zhang, C., Liu, J., Cleveland, J.L., List, A.F. and Wei, S. (2019) S100A9-Induced Overexpression of PD-1/PD-L1 Contributes to Ineffective Hematopoiesis in Myelodysplastic Syndromes. Leukemia, 33, 2034-2046.
https://doi.org/10.1038/s41375-019-0397-9
|
[46]
|
Noman, M.Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V. and Chouaib, S. (2014) PD-L1 Is a Novel Direct Target of HIF-1α, and Its Blockade under Hypoxia Enhanced MDSC-Mediated T Cell Activation. The Journal of Experimental Medicine, 211, 781-790. https://doi.org/10.1084/jem.20131916
|
[47]
|
Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A.J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., Cronin, H., Zhao, X., Schell, M. and Chen, Y.A. (2016) Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunology Research, 4, 345-353.
https://doi.org/10.1158/2326-6066.CIR-15-0193
|
[48]
|
Kaneda, M.M., Messer, K.S., Ralainirina, N., Li, H., Leem, C.J., Gorjestani, S., Woo, G., Nguyen, A.V., Figueiredo, C.C., Foubert, P., Schmid, M.C., Pink, M., Winkler, D.G., Rausch, M., Palombella, V.J., Kutok, J., McGovern, K., Frazer, K.A., Wu, X., Karin, M., et al. (2016) PI3Kγ Is a Molecular Switch That Controls Immune Suppression. Nature, 539, 437-442. https://doi.org/10.1038/nature19834
|
[49]
|
De Henau, O., Rausch, M., Winkler, D., Campesato, L.F., Liu, C., Cymerman, D.H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., Douglas, M., Tibbitts, T., Sharma, S., Proctor, J., Kosmider, N., White, K., Stern, H., Soglia, J., Adams, J., Palombella, V.J., et al. (2016) Overcoming Resistance to Checkpoint Blockade Therapy by Targeting PI3Kγ in Myeloid Cells. Nature, 539, 443-447. https://doi.org/10.1038/nature20554
|
[50]
|
Chen, H.M., van der Touw, W., Wang, Y.S., Kang, K., Mai, S., Zhang, J., Alsina-Beauchamp, D., Duty, J.A., Mungamuri, S.K., Zhang, B., Moran, T., Flavell, R., Aaronson, S., Hu, H.M., Arase, H., Ramanathan, S., Flores, R., Pan, P.Y. and Chen, S.H. (2018) Blocking Immunoinhibitory Receptor LILRB2 Reprograms Tumor-Associated Myeloid Cells and Promotes Antitumor Immunity. The Journal of Clinical Investigation, 128, 5647-5662.
https://doi.org/10.1172/JCI97570
|
[51]
|
Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., Gabrilovich, D. and Pili, R. (2017) Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clinical Cancer Research, 23, 5187-5201. https://doi.org/10.1158/1078-0432.CCR-17-0741
|
[52]
|
Irani, Y.D., Hughes, A., Clarson, J., Kok, C.H., Shanmuganathan, N., White, D.L., Yeung, D.T., Ross, D.M., Hughes, T.P. and Yong, A. (2020) Successful Treatment-Free Remission in Chronic Myeloid Leukaemia and Its Association with Reduced Immune Suppressors and Increased Natural Killer Cells. British Journal of Haematology, 191, 433-441.
https://doi.org/10.1111/bjh.16718
|
[53]
|
Jia, Y., Li, X., Jiang, T., Zhao, S., Zhao, C., Zhang, L., Liu, X., Shi, J., Qiao, M., Luo, J., Liu, S., Han, R., Su, C., Ren, S. and Zhou, C. (2019) EGFR-Targeted Therapy Alters the Tumor Microenvironment in EGFR-Driven Lung Tumors: Implications for Combination Therapies. International Journal of Cancer, 145, 1432-1444.
https://doi.org/10.1002/ijc.32191
|
[54]
|
Feng, P.H., Yu, C.T., Chen, K.Y., Luo, C.S., Wu, S.M., Liu, C.Y., Kuo, L.W., Chan, Y.F., Chen, T.T., Chang, C.C., Lee, C.N., Chuang, H.C., Lin, C.F., Han, C.L., Lee, W.H. and Lee, K.Y. (2018) S100A9+ MDSC and TAM-Mediated EGFR-TKI Resistance in Lung Adenocarcinoma: The Role of RELB. Oncotarget, 9, 7631-7643.
https://doi.org/10.18632/oncotarget.24146
|
[55]
|
Feng, P.H., Lee, K.Y., Chang, Y.L., Chan, Y.F., Kuo, L.W., Lin, T.Y., Chung, F.T., Kuo, C.S., Yu, C.T., Lin, S.M., Wang, C.H., Chou, C.L., Huang, C.D. and Kuo, H.P. (2012) CD14+S100A9+ Monocytic Myeloid-Derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 186, 1025-1036. https://doi.org/10.1164/rccm.201204-0636OC
|
[56]
|
Yu, J., Wang, Y., Yan, F., Zhang, P., Li, H., Zhao, H., Yan, C., Yan, F. and Ren, X. (2014) Noncanonical NF-κB Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer. Journal of Immunology, 193, 2574-2586. https://doi.org/10.4049/jimmunol.1400833
|
[57]
|
Li, F., Zhao, Y., Wei, L., Li, S. and Liu, J. (2018) Tumor-Infiltrating Treg, MDSC, and IDO Expression Associated with Outcomes of Neoadjuvant Chemotherapy of Breast Cancer. Cancer Biology & Therapy, 19, 695-705.
https://doi.org/10.1080/15384047.2018.1450116
|
[58]
|
Carvalho, H.A. and Villar, R.C. (2018) Radiotherapy and Immune Response: The Systemic Effects of a Local Treatment. Clinics, 73, Article No. e557s. https://doi.org/10.6061/clinics/2018/e557s
|
[59]
|
Terry, S., Buart, S. and Chouaib, S. (2017) Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity. Frontiers in Immunology, 8, Article No. 1625.
https://doi.org/10.3389/fimmu.2017.01625
|